MedTrace Logo

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

NCT03024580 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-08-15

No results posted yet for this study

Summary

This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.

Conditions

  • Breast Neoplasm

Interventions

DRUG

Megestrol Acetate 160Mg Tablet

Megestrol acetate 160 mg PO daily

DRUG

Anastrozole 1Mg Tablet

Anastrozole 1 mg PO daily OR

DRUG

Letrozole 2.5Mg Tablet

Letrozole 2.5 mg PO daily OR

DRUG

Exemestane 25 MG

Exemestane 25 mg PO daily

DRUG

Tamoxifen 20Mg Tablet

Tamoxifen 20 mg PO daily

DRUG

Fulvestrant 50Mg Solution for Injection

Fulvestrant 500 mg IM d1, d14, d28 and q28 days

Sponsors & Collaborators

  • Cancer Research UK Cambridge Institute

    collaborator OTHER

  • Instituto Nacional de Cancer, Brazil

    lead OTHER_GOV

Principal Investigators

  • José Bines, MD, PhD · Instituto Nacional de Cancer, Brazil

  • Jason Carroll, PhD · Cancer Research UK Cambridge Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-06
Primary Completion
2020-03-31
Completion
2020-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03024580 on ClinicalTrials.gov